Photo of David Swope

David Swope

Print ProfilePrint Profile



  • Neurology, American Board of Psychiatry and Neurology


  • MD, Loma Linda University

  • Residency, Internal Medicine
    Loma Linda University Medical Ctr.

  • Residency, Neurology
    Loma Linda University Medical Ctr.

  • Fellowship, Movement Disorders
    Mount Sinai Hospital


Brodsky MA, Swope DM, Grimes D. Diffusion of botulinum toxins. Tremor and other hyperkinetic movements (New York, N.Y.) 2012; 2.

Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature [review]. Clinical therapeutics 2012 Jul; 34(7).

Okun MS, Gallo BV, Mandybur G, Jagid J, Foote KD, Revilla FJ, Alterman R, Jankovic J, Simpson R, Junn F, Verhagen L, Arle JE, Ford B, Goodman RR, Stewart RM, Horn S, Baltuch GH, Kopell BH, Marshall F, Peichel D, Pahwa R, Lyons KE, Tröster AI, Vitek JL, Tagliati M. Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet neurology 2012 Feb; 11(2).

Chen JJ, Swope DM, Dashtipour K, Lyons KE. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease [review]. Pharmacotherapy 2009 Dec; 29(12).

Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. The New England Journal of Medicine 2009 Sep; 361(13).

Swope D, Barbano R. Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia [review]. Neurologic clinics 2008 May; 26 Suppl 1.

Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Movement Disorders : official journal of the Movement Disorder Society 2008 Jul; 23(10).

Chen JJ, Swope DM. Pharmacotherapy for Parkinson's disease [review]. Pharmacotherapy 2007 Dec; 27(12 Pt 2).

Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease [review]. Clinical therapeutics 2007 Sep; 29(9).

Obering CD, Chen JJ, Swope DM. Update on apomorphine for the rapid treatment of hypomobility ( [review]. Pharmacotherapy 2006 Jun; 26(6).

Chen JJ, Swope DM. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease [review]. Journal of clinical pharmacology 2005 Aug; 45(8).

Chen JJ, Swope DM. A case of complex movement disorder induced by fluoxetine with management of dystonia by botulinum toxin type A. The Journal of clinical psychiatry 2005 Feb; 66(2).

Chen JJ, Swope DM. Essential tremor: diagnosis and treatment [review]. Pharmacotherapy 2003 Sep; 23(9).

Ramdhani RA, Patel A, Swope D, Kopell BH. Early Use of 60 Hz Frequency Subthalamic Stimulation in Parkinson's Disease: A Case Series and Review. Neuromodulation : journal of the International Neuromodulation Society 2015 Apr;.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Swope during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.


  • Allergan, Inc.; Solstice Neurosciences, LLC (US WorldMeds); Teva Pharmaceutical Industries Ltd.

Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.

  • Allergan, Inc.; Teva Pharmaceutical Industries Ltd.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central


Faculty Practice Associates Floor 1st
5 East 98th Street
New York, NY 10029

Tel: 212-241-5607
Movement Disorder Faculty Practice

5 E. 98th Street
1st Floor
New York, NY 10029

Tel: 212-241-5607
Fax: 212-241-3656
Get Directions

Office Hours:
  • Thursday 9:00am - 5:00pm
  • Friday 9:00am - 5:00pm
Insurance Plans
  • Aetna
  • Blue Cross/ Blue Shield
  • Cigna - HMO
  • GHI
  • Medicare
  • MultiPlan, Inc.
  • Oxford Freedom
  • Oxford Liberty
  • United Healthcare
Payment Methods
  • Master Card
  • Visa
  • American Express
  • Discover
  • Personal Check
  • Cash